Keywords: king, pharma, revises, forecasts, after, elan, unit

King Pharma revises forecasts after Elan unit acquisitions

Article | 10 February 2003

King Pharmaceuticals has announced its projections for estimated totalrevenue, net sales of Altace (ramipril), and estimated earnings per share, before ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

King Pharmaceuticals

Go to company listing

Related Drugs

Altace

Ramipril Tablets

Metaxalone

Skelaxin

Pyrazolopyrimidine

Go to drug listing